On September 24, 2025, Lantheus Holdings, Inc. (NASDAQ: LNTH) and GE HealthCare (NASDAQ: GEHC) announced an exclusive licensing agreement that grants GE HealthCare the rights to develop, manufacture, and commercialize Lantheus’s piflufolastat F‑18 (PYLARIFY) in Japan for prostate cancer diagnostics and companion diagnostic use.
The agreement provides Lantheus with an upfront license fee, development milestone payments, and tiered royalties based on product sales in Japan. A joint steering committee will oversee development and commercialization activities, and GE HealthCare will leverage its recently acquired Nihon Medi‑Physics Co., Ltd. manufacturing network to support the launch.
Strategically, the deal expands Lantheus’s presence into the Japanese market, the third‑largest prostate cancer market worldwide, and positions the company to capture a new revenue stream while benefiting from GE HealthCare’s extensive regional expertise and distribution capabilities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.